Trisenox arsenic trioxide: Phase II data

In a Phase II trial of Trisenox in 67 patients, 6 of 29 low-risk patients and 4 of 33 high-risk patients had a major hematologic response. Trisenox also led to transfusion independence in 5 patients a...